
    
      Patients with verified HoFH on stable and continuing doses of oral lipid lowering therapy
      will be randomized to either evolocumab 420 mg Q4W or LIB003 300 mg Q4W for 24 weeks (Period
      A). At Week 24, subjects will be crossed over to LIB003 if they were on evolocumab and vice
      versa for the next 24 weeks (Period B).
    
  